Kidney function assessment for eligibility in clinical cancer trials – Data from the European Organisation for Research and Treatment of Cancer
This post hoc analysis highlights the importance of choosing accurate and representative methods for kidney function estimation in clinical cancer trials. CG should be replaced by newer methods. While CKD-EPI 2021 may maximize trial accrual, EKFC should be considered for treatment affecting kidney function.
Authors
- Maike Collienne (ORCID: https://orcid.org/0000-0003-0932-2471)
- H.C. Puhr
- Eleni Xenophontos
- Matthias Preusser (ORCID: https://orcid.org/0000-0003-3541-2315)
- Antoine Giraud (ORCID: https://orcid.org/0000-0003-2158-3930)
- Jan Bogaerts (ORCID: https://orcid.org/0000-0003-4216-3679)
- Saskia Litière (ORCID: https://orcid.org/0000-0002-6433-4056)
- Luc Boone
Institutions
- European Organisation for Research and Treatment of Cancer (BE)
- Medical University of Vienna (AT)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2024-08-31
- DOI
- https://doi.org/10.1016/j.ejca.2024.114302
- Citations
- 1
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 0.34